RS52526B2 - Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 - Google Patents
Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842Info
- Publication number
- RS52526B2 RS52526B2 RS20120507A RSP20120507A RS52526B2 RS 52526 B2 RS52526 B2 RS 52526B2 RS 20120507 A RS20120507 A RS 20120507A RS P20120507 A RSP20120507 A RS P20120507A RS 52526 B2 RS52526 B2 RS 52526B2
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- salt
- methyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Claims (15)
- Patentni zahtevi 1. Jedinjenje prema Formuli I:naznačeno time, što R<1>predstavlja halo ili C1-3 haloalkoksil; Q predstavljai R<2>predstavlja vodonik ili C1-3alkil; ili farmaceutski prihvatljiva so, optički izomer, ili kombinacija navedenog jedinjenja ili soli.
- 2. Jedinjenje prema zahtevu 1, naznačeno time što R<1>predstavlja hloro, ili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 3. Jedinjenje prema zahtevu 1, naznačeno time što R<1>predstavlja trifluorometoksil, ili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 4. Jedinjenje prema zahtevu 1, naznačeno time što Q predstavljaili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 5. Jedinjenje prema zahtevu 4, naznačeno time što Q predstavljai R<2>predstavlja H; ili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 6. Jedinjenje prema zahtevu 1, naznačeno time što R<1>predstavlja hloro i Q predstavljaili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 7. Jedinjenje prema zahtevu 1, naznačeno time što R<1>predstavlja trifluorometoksil i Q predstavljaili farmaceutski prihvatljiva so, ili optički izomer navedenog jedinjenja ili soli.
- 8. Jedinjenje ili njegova farmaceutski prihvatljiva so prema zahtevu 1, naznačeni time što se jedinjenje bira između: 7-metil-5-(3-piperazin-l-ilmetil-[l,2,4]oksadiazol-5-il)-2-(4-trifluorometoksi benzil)-2,3- dihidroizoindol-1-ona; 2-(4-hloro-benzil)-5-[3-(2,5-diaza-biciklo[2.2.1]hept-2-ilmetil)-[l,2,4]oksadiazol-5-il]-7-metil-2,3-dihidro-izoindol-1-ona; 2-(4-hloro-benzil)-7-metil-5-[3-(3-metil-piperazin-l-ilmetil)-[l,2,4]oksadiazol-5-il]-2,3-dihidroizoindol-l-ona; 2-(4-hloro-benzil)-7-metil-5-(3-piperazin-l-ilmetil-[l,2,4]oksadiazol-5-il)-2,3-dihidro-izoindol-1- ona; 2- (4-hloro-benzil)-7-metil-5-[3-(2-metil-piperazin-l-ilmetil)-[l,2,4]oksadiazol-5-il]-2,3-dihidro- izoindol-l-ona, ili 2-(4-hloro-benzil)-7-metil-5-[3-(2-metil-piperazin-l-ilmetil)-[l,2,4]oksadiazol-5-il]-2,3-dihidroizoindol-l-ona.
- 9. Jedinjenje ili njegova farmaceutski prihvatljiva so prema zahtevu 1, naznačeno time da je 7-metil-5-(3-piperazin-l-ilmetil-[l,2,4]oksadiazol-5-il)-2-(4-trifluorometoksibenzil)-2,3-dihidroizoindol-l-on.
- 10. Farmaceutski prihvatljiva so 7-metil-5-(3-piperazin-l-ilmetil-[l,2,4]oksadiazol-5-il)-2-(4-trifluorometoksibenzil)-2,3-dihidroizoindol-l-ona prema zahtevu 9, naznačena time da je odabrana od soli hidrohlorida, hidrobromida, fosfata, acetata, fumarata, maleata, tartrata, citrata, metansulfonata ili p-toluensulfonata.
- 11. Farmaceutska smeša, naznačena time što sadrži jedinjenje ili so prema bilo kojem od zahteva 1-10 i farmaceutski prihvatljiv nosač ili ekscipijent.
- 12. Jedinjenje ili so prema bilo kojem od zahteva 1-10, naznačeni time što se koriste u tretmanu subjekta koji boluje od neuroloških ili psihijatrijskih poremećaja vezanih sa disfunkcijom glutamata.
- 13. Jedinjenje za korišćenje prema zahtevu 12, naznačeno time što se neurološki ili psihijatrijski poremećaj odabire između Alchajmerove bolesti, cerebralnih deficita nakon prolongiranog statusa epileptikusa, tolerancije na supstance, simptoma odvikavanja od supstanci, psihoze, šizofrenije, anksioznosti, generalizovanog anksioznog poremećaja, paničnog poremećaja, društvene fobije, opsesivno kompulzivnog poremećaja i post traumatskog stresnog poremećaja, poremećaja raspoloženja, depresije, manije ili bipolarnih poremećaja.
- 14. Korišćenje jedinjenja ili soli prema bilo kojem od zahteva 1 - 10, naznačeno time što mu je namena priređivanje medikamenta za terapiju neuroloških ili psihijatrijskih poremećaja povezanih sa disfunkcijom glutamata.
- 15. Korišćenje prema zahtevu 14, naznačeno time što se neurološki ili psihijatrijski poremećaj odabire između Alchajmerove bolesti, cerebralnih deficita nakon prolongiranog statusa epileptikusa, tolerancije na supstance, simptome odvikavanja od supstanci, psihoze, šizofrenije, anksioznosti, generalizovanog anksioznog poremećaja, paničnog poremećaja, društvene fobije, opsesivno kompulzivnog poremećaja i post traumatskog stresnog poremećaja, poremećaja raspoloženja, depresije, manije ili bipolarnih poremećaja. Izdaje i štampa: Zavod za intelektualnu svojinu, Beograd, Kneginje Ljubice 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94255307P | 2007-06-07 | 2007-06-07 | |
| EP08779348.5A EP2167502B3 (en) | 2007-06-07 | 2008-06-05 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 |
| PCT/SE2008/050666 WO2008150233A1 (en) | 2007-06-07 | 2008-06-05 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RS52526B RS52526B (sr) | 2013-04-30 |
| RS52526B2 true RS52526B2 (sr) | 2018-06-29 |
Family
ID=40093925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150130A RS53845B1 (sr) | 2007-06-07 | 2008-06-05 | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 |
| RS20120507A RS52526B2 (sr) | 2007-06-07 | 2008-06-05 | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150130A RS53845B1 (sr) | 2007-06-07 | 2008-06-05 | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8377940B2 (sr) |
| EP (2) | EP2444399B1 (sr) |
| JP (2) | JP5416696B2 (sr) |
| KR (2) | KR20150116907A (sr) |
| CN (2) | CN101679403B (sr) |
| AR (1) | AR066882A1 (sr) |
| AU (1) | AU2008260717B2 (sr) |
| BR (1) | BRPI0812889A2 (sr) |
| CA (1) | CA2690856C (sr) |
| CL (1) | CL2008001667A1 (sr) |
| CO (1) | CO6251287A2 (sr) |
| CY (2) | CY1113422T1 (sr) |
| DK (2) | DK2167502T3 (sr) |
| EC (1) | ECSP109856A (sr) |
| ES (2) | ES2531443T3 (sr) |
| HR (2) | HRP20120909T4 (sr) |
| IL (1) | IL202158A (sr) |
| ME (1) | ME01488B (sr) |
| MX (1) | MX2009013078A (sr) |
| MY (1) | MY158066A (sr) |
| NZ (1) | NZ582445A (sr) |
| PE (1) | PE20090328A1 (sr) |
| PL (2) | PL2444399T3 (sr) |
| PT (2) | PT2167502E (sr) |
| RS (2) | RS53845B1 (sr) |
| RU (2) | RU2470931C2 (sr) |
| SA (1) | SA08290344B1 (sr) |
| SI (2) | SI2444399T1 (sr) |
| TW (1) | TWI417100B (sr) |
| UA (1) | UA99129C2 (sr) |
| UY (1) | UY31124A1 (sr) |
| WO (1) | WO2008150233A1 (sr) |
| ZA (1) | ZA200908285B (sr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807706B2 (en) * | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| US7868008B2 (en) * | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| TW200804281A (en) * | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| BRPI0816970A2 (pt) | 2007-09-14 | 2015-03-24 | Ortho Mcneil Janssen Pharm | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas |
| CA2704436C (en) * | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SA109300358B1 (ar) * | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
| CA2728675A1 (en) | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Dibenzothiazepine derivatives and use thereof |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| US20130203995A1 (en) | 2010-01-07 | 2013-08-08 | Astrazeneca Ab | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 |
| CN102858766A (zh) * | 2010-04-30 | 2013-01-02 | 阿斯利康(瑞典)有限公司 | 亲代谢性谷氨酸盐受体正变构调节剂的多晶型物 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN102180872B (zh) * | 2011-04-01 | 2014-04-02 | 华中科技大学 | [1,3,4]噁二唑类衍生物及其应用 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| US10357484B2 (en) * | 2015-07-17 | 2019-07-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
| WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| IL289891B2 (en) * | 2019-07-18 | 2025-06-01 | Abaxys Therapeutics | Solid formulation of a 1,2,4-oxadiazole derivative |
| GB2621323A (en) * | 2022-08-03 | 2024-02-14 | Sirgartan Holdings Ltd | Treatments for obsessive compulsive disorder |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2008803A (en) * | 1932-04-18 | 1935-07-23 | Stephan Engineering Corp | Fuel atomizing and igniting means |
| US3993617A (en) | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
| US5175157A (en) | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| WO1992017448A1 (fr) | 1991-04-01 | 1992-10-15 | Kyowa Hakko Kogyo Co., Ltd. | Derive de 3-methylenisoindolin-1-one |
| TW219935B (sr) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| EP0602814A1 (en) | 1992-12-18 | 1994-06-22 | Takeda Chemical Industries, Ltd. | Crystal forms of optically active isoindolines and their use |
| US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| US6017919A (en) | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
| EP0999208A4 (en) | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| AU771358B2 (en) | 1997-11-21 | 2004-03-18 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| NZ521576A (en) | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| HUP0302966A2 (hu) | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| RU2270192C2 (ru) * | 2001-04-19 | 2006-02-20 | Эйсай Ко., Лтд. | Производные 2-иминопирролидина |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
| FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB0223232D0 (en) | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| CN100548980C (zh) * | 2002-11-26 | 2009-10-14 | 丸石制药株式会社 | 异吲哚啉衍生物 |
| AU2004226450A1 (en) | 2003-03-26 | 2004-10-14 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
| GB0308025D0 (en) | 2003-04-07 | 2003-05-14 | Glaxo Group Ltd | Compounds |
| US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| JP2007510629A (ja) | 2003-10-22 | 2007-04-26 | イーライ リリー アンド カンパニー | 新規ｍｃｈ受容体アンタゴニスト |
| JP2007519754A (ja) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| ATE402935T1 (de) * | 2004-02-18 | 2008-08-15 | Astrazeneca Ab | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen |
| BRPI0508140B1 (pt) | 2004-03-05 | 2015-03-17 | Nissan Chemical Ind Ltd | Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo" |
| AU2005219791B2 (en) | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| AU2005299797A1 (en) | 2004-10-25 | 2006-05-04 | Merck & Co., Inc. | Heterocyclic indanone potentiators of metabotropic glutamate receptors |
| CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| WO2006123255A2 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
| JP5031745B2 (ja) * | 2005-08-12 | 2012-09-26 | アストラゼネカ アクチボラグ | 代謝型グルタミン酸受容体増強性イソインドロン |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| ATE463495T1 (de) * | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
-
2008
- 2008-06-04 TW TW097120762A patent/TWI417100B/zh not_active IP Right Cessation
- 2008-06-05 UA UAA200911794A patent/UA99129C2/ru unknown
- 2008-06-05 KR KR1020157026785A patent/KR20150116907A/ko not_active Ceased
- 2008-06-05 AU AU2008260717A patent/AU2008260717B2/en not_active Ceased
- 2008-06-05 HR HRP20120909AT patent/HRP20120909T4/hr unknown
- 2008-06-05 US US12/663,371 patent/US8377940B2/en not_active Expired - Fee Related
- 2008-06-05 WO PCT/SE2008/050666 patent/WO2008150233A1/en not_active Ceased
- 2008-06-05 CN CN2008800191548A patent/CN101679403B/zh not_active Expired - Fee Related
- 2008-06-05 NZ NZ582445A patent/NZ582445A/en not_active IP Right Cessation
- 2008-06-05 RS RS20150130A patent/RS53845B1/sr unknown
- 2008-06-05 MX MX2009013078A patent/MX2009013078A/es active IP Right Grant
- 2008-06-05 PL PL11195016T patent/PL2444399T3/pl unknown
- 2008-06-05 ES ES11195016.8T patent/ES2531443T3/es active Active
- 2008-06-05 RS RS20120507A patent/RS52526B2/sr unknown
- 2008-06-05 JP JP2010511147A patent/JP5416696B2/ja not_active Expired - Fee Related
- 2008-06-05 PT PT08779348T patent/PT2167502E/pt unknown
- 2008-06-05 DK DK08779348.5T patent/DK2167502T3/da active
- 2008-06-05 CA CA2690856A patent/CA2690856C/en not_active Expired - Fee Related
- 2008-06-05 KR KR1020097025404A patent/KR20100017640A/ko not_active Ceased
- 2008-06-05 EP EP11195016.8A patent/EP2444399B1/en active Active
- 2008-06-05 AR ARP080102401A patent/AR066882A1/es unknown
- 2008-06-05 MY MYPI20095187A patent/MY158066A/en unknown
- 2008-06-05 CN CN201210486921.4A patent/CN102977086B/zh not_active Expired - Fee Related
- 2008-06-05 ES ES08779348T patent/ES2393425T7/es active Active
- 2008-06-05 PL PL08779348T patent/PL2167502T6/pl unknown
- 2008-06-05 SI SI200831385T patent/SI2444399T1/sl unknown
- 2008-06-05 BR BRPI0812889A patent/BRPI0812889A2/pt not_active IP Right Cessation
- 2008-06-05 EP EP08779348.5A patent/EP2167502B3/en active Active
- 2008-06-05 RU RU2009147708/04A patent/RU2470931C2/ru not_active IP Right Cessation
- 2008-06-05 ME MEP-2012-131A patent/ME01488B/me unknown
- 2008-06-05 SI SI200830807T patent/SI2167502T1/sl unknown
- 2008-06-05 PT PT11195016T patent/PT2444399E/pt unknown
- 2008-06-05 DK DK11195016T patent/DK2444399T3/en active
- 2008-06-06 US US12/134,553 patent/US8377939B2/en not_active Expired - Fee Related
- 2008-06-06 UY UY31124A patent/UY31124A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2008000965A patent/PE20090328A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001667A patent/CL2008001667A1/es unknown
- 2008-06-07 SA SA08290344A patent/SA08290344B1/ar unknown
-
2009
- 2009-11-16 IL IL202158A patent/IL202158A/en not_active IP Right Cessation
- 2009-11-23 ZA ZA200908285A patent/ZA200908285B/xx unknown
- 2009-12-04 CO CO09139153A patent/CO6251287A2/es not_active Application Discontinuation
-
2010
- 2010-01-06 EC EC2010009856A patent/ECSP109856A/es unknown
-
2012
- 2012-09-25 RU RU2012141706/04A patent/RU2012141706A/ru not_active Application Discontinuation
- 2012-11-22 CY CY20121101132T patent/CY1113422T1/el unknown
-
2013
- 2013-11-14 JP JP2013235538A patent/JP5815644B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-24 HR HRP20150210TT patent/HRP20150210T1/hr unknown
- 2015-02-26 CY CY20151100204T patent/CY1116150T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01488B (me) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| JP5894574B2 (ja) | 有機化合物 | |
| JP6475727B2 (ja) | 新規方法 | |
| CN1060775C (zh) | 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物 | |
| ES2362326T3 (es) | Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor nicotínico alfa 7 de la acetilcolina para el tratamiento de enfermedad de alzheimer. | |
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| JP2012526736A5 (sr) | ||
| US20100184775A1 (en) | Organic compounds | |
| JP2008513496A5 (sr) | ||
| JP2012526735A5 (sr) | ||
| JP2010504352A5 (sr) | ||
| JP2010535858A5 (sr) | ||
| JP2008505107A5 (sr) | ||
| CA2695742A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| JP2018538253A5 (sr) | ||
| JP2019537592A5 (sr) | ||
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| JP4813357B2 (ja) | Ｎ−ビアリールアミド化合物 | |
| EA200701345A1 (ru) | Производные триазолона, тетразолона и имидазолона для применения в качестве антагонистов альфа-2с-адренорецептора | |
| JP2004529936A5 (sr) | ||
| AR058199A1 (es) | Derivados de 3- alquilazetidina sustituidos con heterociclos | |
| US20080312253A1 (en) | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | |
| JP2010505919A5 (sr) | ||
| RU2007110479A (ru) | Производные бензоксазина и хиноксалина, и их применение | |
| JP2003513072A5 (sr) |